Publications

This Pompe disease review considered alglucosidase alfa. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This Gaucher disease review considered three enzyme replacement therapies (ERTs), imiglucerase, velaglucerase and taliglucerase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This document looks at the improvements to the National Framework for Alcohol, Tobacco and other Drug Treatment. It looks at improving processes for communication, coordination, and collaboration (CCC) between and amongst alcohol and other drug (AOD) treatment funders.

This fact sheet gives answers to common questions about the role of pharmacies and authorised persons in managing Life Saving Drugs Program (LSDP) medicines.

This presentation, delivered on 25 January 2023, contains an update to Australia's COVID-19 vaccine rollout.

This data file contains statistical data about Australia's COVID-19 vaccinations.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

A list of National Health and Medical Research Council (NHMRC) projects and the committed funding.

An update from the Council of Elders after their meeting on 8 and 9 December, 2022.

The meeting of the National Aged Care Advisory Council was held on 15 December 2022.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS I review considered laronidase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumer

This Fabry disease review considered the two enzyme replacement therapies (ERTs), agalsidase alfa and agalsidase beta. The Expert Panel considered this review at its October 2020 meeting. These documents provide a summary of the review findings and recommendations.

This spreadsheet classifies MBS items by private health insurance clinical category and procedure type and includes MBS items commencing 1 March 2023.

These reports list the percentage of people who have been vaccinated against COVID-19 by local government area (LGA).

This infographic issued on 20 January 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

This report, and accompanying table, provide a fortnightly summary on notifications of Australia's nationally notifiable diseases for 12 December 2022 to 8 January 2023

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

Health Technology Assessment Policy and Methods Review Reference Committee agenda for the 3rd meeting on 27 January 2023.

A update from the Health Technology Assessment Policy and Methods review Reference Committee following their meeting on 1 December and 19 December 2022.

This document covers the evidence on the currently recognised severe tick-induced allergies.

This document covers prevention and management of tick bites for people living in Australia.

This document covers Australian tick-borne diseases.

This document provides evidence-based guidance for clinicians in community and hospital settings, as well as providing a reference source on DSCATT topics. This Guidance Note covers overseas-acquired Lyme disease.